News
Post Doctoral Scientist post available at Boehringer - Research Beyond Borders working with the UK Cystic Fibrosis Gene Therapy Consortium
1 year ago The UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
1 year ago Flutterby Fundraisers to Sponsor Consortium Scientist
2 years ago New Publication - Gelinas et al 2017 - Media Supplements to Improve Lentiviral Vector Production Yields
2 years ago Gene Therapy Funding Update
2 years ago Consortium Student Live Facebook Interview from ASGCT
2 years ago
1 year ago The UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim, Imperial Innovations and Oxford BioMedica Announce New Partnership to Develop First-In-Class Gene Therapy for Cystic Fibrosis
1 year ago Flutterby Fundraisers to Sponsor Consortium Scientist
2 years ago New Publication - Gelinas et al 2017 - Media Supplements to Improve Lentiviral Vector Production Yields
2 years ago Gene Therapy Funding Update
2 years ago Consortium Student Live Facebook Interview from ASGCT
2 years ago
Latest News
Consortium Featured in Observer Magazine
The work of the Consortium was featured in an Observer Magazine article by Robin McKie.
10 years ago
VGXi Sign Deal to Manufacture DNA for the Consortium
VGXi Pharmaceuticals sign a multi-year production agreement with the United Kingdom Cystic Fibrosis Gene Therapy Consortium.
11 years ago
Ian Pringle Wins Outstanding Young Scientist Award at BSGT
Consortium Scientist Dr Ian Pringle won the Lez Fairbairn award for the Outstanding Young Scientist at the BSGT Conference in London
14 years ago
What is Gene Therapy? (2008): CF gene therapy aims to insert a fully functional CFTR gene into the lung airway cells of people with the condition. Two main types of vector are used to deliver this new copy of the gene. A viral vector, engineered from viral particles or non-viral vectors, plasmid DNA molecules condensed by other chemical entities. More...
